VIVOS INC
Close on Oct 19, 2026
- Market cap
- $23.44M
- P/E (TTM)
- –
- Dividend yield
- –
About Vivos
Surgical & Medical Instruments & Apparatus, SIC 3841
Vivos Inc. is a radiation oncology medical device company focused on developing precision radionuclide therapy products. Its core technologies utilize yttrium-90 (Y-90) and include RadioGel for treating solid tumors and positive surgical margins in humans, alongside IsoPet for targeting solid tumors in veterinary patients. The company operates through human and animal therapy divisions, with the latter providing direct treatments and clinic certifications. It also sells PLGA-g-PEG polymers and PrecisionGel, a hydrogel platform designed for delivering active pharmaceutical ingredients and therapeutic agents.
The company is headquartered in Kennewick, Washington. Its operations encompass clinical collaborations across multiple university veterinary hospitals and research laboratories within the United States. In addition, the firm conducts clinical testing activities and is establishing international operations in India through a wholly owned subsidiary based in Mumbai. Domestic production facilities are located in Richland, Washington, serving both animal and human therapy product lines.
Summary of the business section of Vivos's latest annual report, written by StockData.
Company profile
Company
- Legal name
- VIVOS INC
- Headquarters
- Richland, WA
- Address
- 719 Jadwin Avenue 99352
- Phone
- (509) 736-4000
- Employees
- 1, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Fruci & Associates II, PLLC, Spokane, Washington
Stock & identifiers
- Ticker
- RDGL
- Exchange
- OTC
- Shares outstanding
- 494M, Aug 12, 2026
- Public float
- $47.71M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-8 reverse, Aug 13, 2019; 1-for-8 reverse, Jun 28, 2019; 1-for-100 reverse, Nov 21, 2016; 1-for-100 reverse, Oct 11, 2016
- SEC CIK
- 1449349
- EIN
- 80-0138937
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael K. Korenko | CEO AND PRESIDENT, Director | 11,435,090 |
| Brad Allan Weeks | President | 1,547,204 |
Employees
Headcount reported in annual reports
“Since 2017, the Company has followed the cost-effective model of having had one full-time employee, the CEO.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 14, 2018 | Late filing | Notification of late filing |
| May 15, 2018 | Late filing | Notification of late filing |
| Dec 18, 2017 | Name change | Name changed from ADVANCED MEDICAL ISOTOPE Corp to VIVOS INC |
| Nov 15, 2016 | Late filing | Notification of late filing |
| Sep 2, 2016 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 25, 2016 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 15, 2016 | Late filing | Notification of late filing |
| May 17, 2016 | Late filing | Notification of late filing |
| Mar 30, 2016 | Late filing | Notification of late filing |
| Jan 19, 2016 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 16, 2015 | Late filing | Notification of late filing |
| Aug 14, 2015 | Late filing | Notification of late filing |
| Mar 31, 2015 | Late filing | Notification of late filing |
| Nov 16, 2009 | Late filing | Notification of late filing |
| Aug 14, 2009 | Late filing | Notification of late filing |
| May 15, 2009 | Late filing | Notification of late filing |
| Mar 31, 2009 | Late filing | Notification of late filing |